Search

Your search keyword '"FREDI, MICAELA"' showing total 371 results
Start Over Author "FREDI, MICAELA"
371 results on '"FREDI, MICAELA"'

51. Managing puerperium in patients with systemic autoimmune diseases: an update

Author

Nalli, Cecilia, primary, Manfredi, Lucia, additional, Fredi, Micaela, additional, Crisafulli, Francesca, additional, Bertocchi, Stefania, additional, Khizroeva, Jamilya, additional, Bitsadze, Victoria, additional, Makatsariya, Alexander, additional, Zatti, Sonia, additional, Andreoli, Laura, additional, Franceschini, Franco, additional, and Tincani, Angela, additional

Published
2022
Full Text
View/download PDF

53. Glucocorticoid tapering and associated outcome in patients with newly diagnosed systemic lupus erythematosus: the real-world GULP prospective observational study

Author

Alberto, Floris, Elisabetta, Chessa, Gian Domenico Sebastiani, Immacolata, Prevete, Florenzo, Iannone, Laura, Coladonato, Marcello, Govoni, Alessandra, Bortoluzzi, Marta, Mosca, Chiara, Tani, Andrea, Doria, Luca, Iaccarino, Franceschini, Franco, Fredi, Micaela, Fabrizio, Conti, Francesca Romana Spinelli, Francesca, Bellisai, Roberto, D'Alessandro, Anna, Zanetti, Greta, Carrara, Carlo Alberto Scirè, Alberto, Cauli, Matteo, Piga, study group on Early SLE of the Italian Society of Rheumatology (SIR), Floris, A, Chessa, E, Sebastiani, G, Prevete, I, Iannone, F, Coladonato, L, Govoni, M, Bortoluzzi, A, Mosca, M, Tani, C, Doria, A, Iaccarino, L, Franceschini, F, Fredi, M, Conti, F, Spinelli, F, Bellisai, F, D'Alessandro, R, Zanetti, A, Carrara, G, Scire, C, Cauli, A, and Piga, M

Subjects
glucocorticoids, Immunology, Immunosuppressive Agent, systemic lupus erythematosus, therapeutics, Glucocorticoid, Rheumatology, Humans, Lupus Erythematosus, Systemic, Prednisone, Immunology and Allergy, Prospective Studies, Immunosuppressive Agents, Human
Abstract

ObjectiveA subanalysis of the multicentre Early Lupus inception cohort was performed to investigate the real-world Glucocorticoids (GCs) Use in newly diagnosed systemic lupus erythematosus (SLE) Patients (GULP).MethodsPatients starting prednisone (PDN) ≥5 mg/day and concomitant hydroxychloroquine or immunosuppressant within 12 months of SLE classification were enrolled. Core set variables were recorded at baseline and every 6 months, including changes in PDN dose, European Consensus Lupus Activity Measurement (ECLAM) and Systemic Lupus International Collaborating Clinics damage index. Regression models analysed predictors of tapering PDNResultsThe GULP study included 127 patients with SLE; 73 (57.5%) tapered and maintained PDN ConclusionTapering PDN

Published
2022

55. Anti-SSA/Ro positivity and congenital heart block: obstetric and foetal outcome in a cohort of anti-SSA/Ro positive pregnant patients with and without autoimmune diseases

Author

Fredi, Micaela, primary, Argolini, Lorenza Maria, additional, Angeli, Fabrizio, additional, Trespidi, Laura, additional, Ramoni, Veronique, additional, Zatti, Sonia, additional, Vojinovic, Tamara, additional, Donzelli, Davide, additional, Gazzola, Federica Giulia, additional, Xoxi, Blerina, additional, Andreoli, Laura, additional, Lojacono, Andrea, additional, Ferrazzi, Enrico, additional, Montecucco, Carlomaurizio, additional, Chighizola, Cecilia Beatrice, additional, Meroni, Pier Luigi, additional, Franceschini, Franco, additional, Cimaz, Rolando, additional, Caporali, Roberto, additional, Tincani, Angela, additional, and Gerosa, Maria, additional

Published
2022
Full Text
View/download PDF

56. Second Wave Antibodies in Autoimmune Renal Diseases: The Case of Lupus Nephritis

Author

Angeletti, Andrea, primary, Bruschi, Maurizio, additional, Moroni, Gabriella, additional, Sinico, Renato Alberto, additional, Franceschini, Franco, additional, Fredi, Micaela, additional, Vaglio, Augusto, additional, Cavagna, Lorenzo, additional, Petretto, Andrea, additional, Pratesi, Federico, additional, Migliorini, Paola, additional, Locatelli, Francesco, additional, Pazzola, Giulia, additional, Pesce, Giampaola, additional, Bagnasco, Marcello, additional, Manfredi, Angelo, additional, Ramirez, Giuseppe A., additional, Esposito, Pasquale, additional, Murdaca, Giuseppe, additional, Negrini, Simone, additional, Cipriani, Leda, additional, Trezzi, Barbara, additional, Emmi, Giacomo, additional, Cavazzana, Ilaria, additional, Binda, Valentina, additional, d’Alessandro, Matteo, additional, Fenaroli, Paride, additional, Pisani, Isabella, additional, Garibotto, Giacomo, additional, Montecucco, Carlomaurizio, additional, Santoro, Domenico, additional, Scolari, Francesco, additional, Volpi, Stefano, additional, Mosca, Marta, additional, Tincani, Angela, additional, Candiano, Giovanni, additional, Prunotto, Marco, additional, Verrina, Enrico, additional, Ravelli, Angelo, additional, and Ghiggeri, Gian Marco, additional

Published
2021
Full Text
View/download PDF

57. Early disease and low baseline damage predict response to belimumab in patients with systemic lupus erythematosus

Author

Gatto, Mariele, Saccon, Francesca, Zen, Margherita, Regola, Francesca, Fredi, Micaela, Andreoli, Laura, Tincani, Angela, Urban, Maria Letizia, Emmi, Giacomo, Ceccarelli, Fulvia, Conti, Fabrizio, Bortoluzzi, Alessandra, Govoni, Marcello, Tani, Chiara, Mosca, Marta, Ubiali, Tania, Gerosa, Maria, Bozzolo, Enrica, Canti, Valentina, Cardinaletti, Paolo, Gabrielli, Armando, Tanti, Giacomo, Gremese, Elisa, De Marchi, Ginevra, De Vita, Salvatore, Fasano, Serena, Ciccia, Francesco, Pazzola, Giulia, Salvarani, Carlo, Negrini, Simone, Puppo, Francesco, Di Matteo, Andrea, De Angelis, Rossella, Orsolini, Giovanni, Rossini, Maurizio, Faggioli, Paola, Laria, Antonella, Piga, Matteo, Mathieu, Alessandro, Scarpato, Salvatore, Rossi, Francesca W, de Paulis, Amato, Brunetta, Enrico, Ceribelli, Angela, Selmi, Carlo, Prete, Marcella, Racanelli, Vito, Vacca, Angelo, Bartoloni, Elena, Gerli, Roberto, Larosa, Maddalena, Iaccarino, Luca, Doria, Andrea, Gatto, Mariele, Saccon, Francesca, Zen, Margherita, Regola, Francesca, Fredi, Micaela, Andreoli, Laura, Tincani, Angela, Urban, Maria Letizia, Emmi, Giacomo, Ceccarelli, Fulvia, Conti, Fabrizio, Bortoluzzi, Alessandra, Govoni, Marcello, Tani, Chiara, Mosca, Marta, Ubiali, Tania, Gerosa, Maria, Bozzolo, Enrica, Canti, Valentina, Cardinaletti, Paolo, Gabrielli, Armando, Tanti, Giacomo, Gremese, Elisa, De Marchi, Ginevra, De Vita, Salvatore, Fasano, Serena, Ciccia, Francesco, Pazzola, Giulia, Salvarani, Carlo, Negrini, Simone, Puppo, Francesco, Di Matteo, Andrea, De Angelis, Rossella, Orsolini, Giovanni, Rossini, Maurizio, Faggioli, Paola, Laria, Antonella, Piga, Matteo, Mathieu, Alessandro, Scarpato, Salvatore, Rossi, Francesca W, de Paulis, Amato, Brunetta, Enrico, Ceribelli, Angela, Selmi, Carlo, Prete, Marcella, Racanelli, Vito, Vacca, Angelo, Bartoloni, Elena, Gerli, Roberto, Larosa, Maddalena, Iaccarino, Luca, and Doria, Andrea

Subjects
remission, immune system diseases, LDA, SLE, skin and connective tissue diseases, belimumab, damage
Abstract

To investigate predictors of response, remission, low disease activity (LDA), damage and drug discontinuation in patients with systemic lupus erythematosus (SLE) treated with belimumab.

Published
2020

58. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry

Author

Anja, Strangfeld, Martin, Schäfer, Milena, A Gianfrancesco, Saskia, Lawson-Tovey, Jean, W Liew, Lotta, Ljung, Elsa, F Mateus, Christophe, Richez, Maria, J Santos, Gabriela, Schmajuk, Carlo, A Scirè, Emily, Sirotich, Jeffrey, A Sparks, Paul, Sufka, Thierry, Thomas, Laura, Trupin, Zachary, S Wallace, Sarah, Al-Adely, Javier, Bachiller-Corral, Suleman, Bhana, Patrice, Cacoub, Loreto, Carmona, Ruth, Costello, Wendy, Costello, Laure, Gossec, Rebecca, Grainger, Eric, Hachulla, Rebecca, Hasseli, Jonathan, S Hausmann, Kimme, L Hyrich, Zara, Izadi, Lindsay, Jacobsohn, Patricia, Katz, Lianne, Kearsley-Fleet, Philip, C Robinson, Jinoos, Yazdany, Pedro, M Machado, COVID-19 Global Rheumatology Alliance, COVID-19 Global Rheumatology Alliance Consortium Collaborators: COVID-19 Global Rheumatology Alliance Consortium, Brahim, Dahou, Marcelo, Pinheiro, Francinne, M Ribeiro, Anne-Marie, Chassin-Trubert, Sebastián, Ibáñez, Lingli, Dong, Lui, Cajas, Hesham, Hamoud, Jérôme, Avouac, Véronique, Belin, Raphaël, Borie, Pascal, Chazerain, Xavier, Chevalier, Pascal, Claudepierre, Gaëlle, Clavel, Marie-Eve, Colette-Cedoz, Bernard, Combe, Elodie, Constant, Nathalie, Costedoat-Chalumeau, Marie, Desmurs, Valérie, Devauchelle-Pensec, Mathilde, Devaux, Robin, Dhote, Yannick, Dieudonné, Fanny, Domont, Pierre-Marie, Duret, Mikaël, Ebbo, Esther, Ebstein, Soumaya El Mahou, Bruno, Fautrel, Renaud, Felten, René-Marc, Flipo, Violaine, Foltz, Antoine, Froissart, Joris, Galland, Véronique, Gaud-Listrat, Sophie, Georgin-Lavialle, Aude, Giraud-Morelet, Jeanine, S Giraudet-Le Quitrec, Philippe, Goupille, Sophie, Govindaraju-Audouard, Franck, Grados, Séverine, Guillaume-Czitrom, Marion, Hermet, Ambre, Hittinger-Roux, Christophe, Hudry, Isabelle, Kone-Paut, Sylvain La Batide Alanore, Pierre, Lafforgue, Sophie, Lahalle, Isabelle, Lambrecht, Vincent, Langlois, Jean-Paul, Larbre, Emmanuel, Ledoult, Christophe, Leroux, Frédéric, Liote, Alexandre TJ Maria, Hubert, Marotte, Arsène, Mekinian, Isabelle, Melki, Laurent, Messer, Catherine, Michel, Gauthier, Morel, Jacques, Morel, Marie-Noelle, Paris-Havard, Edouard, Pertuiset, Thao, Pham, Myriam, Renard, Sabine, Revuz, Sébastien, Rivière, Clémentine, Rousselin, Christian, Roux, Diane, Rouzaud, Jérémie, Sellam, Raphaele, Seror, Amelie, Servettaz, Vincent, Sobanski, Christelle, Sordet, Lionnel, Spielmann, Nathalie, Tieulié, Alice, Tison, Sophie, Trijau, Alexandre, Virone, Ursula, Warzocha, Daniel, Wendling, Frederik, N Albach, Peer, Aries, Elvira, Decker, Urs, Hartmann, Joerg, Henes, Bimba, F Hoyer, Andreas, Krause, Klaus, Krüger, Hanns-Martin, Lorenz, Ulf, Müller-Ladner, Alexander, Pfeil, Anne, Regierer, Jutta, G Richter, Markus, Rihl, Tim, Schmeiser, Hendrik, Schulze-Koops, Christof, Specker, Reinhard, E Voll, Stephanie, Werner, Gabriela MG Melgar, Mahdi, Vojdanian, Andreoli, Laura, Elena, Bartoloni-Bocci, Maurizio, Benucci, Francesco, Campanaro, Marta, Caprioli, Davide, Carboni, Greta, Carrara, Edoardo, Cipolletta, Chiara, Crotti, Gloria, Dallagiacoma, Paola, Faggioli, Rosario, Foti, Franceschini, Franco, Fredi, Micaela, Giacomo, Guidelli, Florenzo, Iannone, Gianpiero, Landolfi, Caludia, Lomater, Ceciclia, Nalli, Simone, Parisi, Luca, Quartuccio, Bernd, Raffeiner, Rossella, Reggia, Marta, Riva, Nicoletta, Romeo, Cinzia, Rotondo, Ettore, Silvagni, Luigi, Sinigaglia, Ilaria, Tinazzi, Anna, Zanetti, Giovanni, Zanframundo, Fatemah, Abutiban, Deshiré, Alpízar-Rodríguez, Marina, R Gabayet, Fedra, Irazoque, Xochitl, Jimenez, Eduardo, Martín, Angel AC Ortiz, Tatiana, S Rodriguez-Reyna, Diana, C Rosete, Erick AZ Tehozol, David, Vega, Beatriz, Zaueta, Nasra, Al-Adhoubi, Babur, Salim, Enrique, Giraldo, Ariel, Salinas, Manuel, Ugarte-Gil, Diogo, Almeida, Miguel, Bernardes, Rita, C Machado, Maria, Rato, Samar, Al-Emadi, Richard, Conway, Rachael, Flood, Juan, J Alegre-Sancho, Montserrat, C Coro, Natalia de la Torre-Rubio, Jose, C Esteban, Maria del Martin, Jose, G Puerta, Johan, Back, Maryam, Dastmalchi, Brigitte, Dupré, Emma, Grenholm, Aase, Hensvold, Ann, Knight, Servet, Akar, Ozan, C Icacan, Laura, Chadwick, Kirsty, Devine, Sasha, Dunt, Lucia, Fusi, Caroline, M Jones, Elizabeth, Macphie, Elena, Nikiphorou, Diana, O'Kane, Sheila, O'Reilly, Samir, Patel, Rosaria, Salerno, Lucy, Thornton, Jenny, Tyler, Claire, Vandevelde, Elizabeth, Warner, Su-Ann, Yeoh, Sara, Baig, Hammad, Bajwa, Byung, Ban, Vernon, Berglund, Cassandra, Calabrese, Kristin, D'Silva, Angela, Dahle, Kathryn, Dao, Nicole, Daver, William, Davis, Walter, Dorman, Ezzati, Fatemeh, Theodore, Fields, Jody, Hargrove, Melissa, Harvey, Maren, Hilton, Tiffany, Hsu, Arundathi, Jayatilleke, David, Karp, Gilbert, Kepecs, Neil, Kramer, Concetta, Lamore, Nicholas, Lebedoff, Susan, Leonard, Sushama, Mody, Jennifer, Morgan, Emily, Pfeifer, Guillermo, Quiceno, Robert, Quinet, Elliot, Rosenstein, Eric, Ruderman, Evangeline, Scopelitis, Naomi, Serling-Boyd, Faizah, Siddique, Archibald, Skemp, Jeffrey, Sparks, Derrick, Todd, Karen, T Toribio, Rachel, Wallwork, Tameka, Webb-Detiege, Douglas, White, Jeffrey, Wilson, Melanie, Winter, Leanna, Wise, Anne, Wolff, Kristen, Young, Jerald, Zakem, Joann, Zell, and Kurt Zimmerman, Leibniz Forschungsinstitut für Molekulare Pharmakolgie = Leibniz Institute for Molecular Pharmacology [Berlin, Allemagne] (FMP), Leibniz Association, University of California, University of Manchester [Manchester], Boston University School of Medicine (BUSM), Boston University [Boston] (BU), Umeå University, EULAR standing committee of People with Arthritis/Rheumatism in Europe (PARE), CHU Bordeaux [Bordeaux], Club Rhumatismes et Inflammation, Faculdade de Medicina [Lisboa], Universidade de Lisboa (ULISBOA), Università degli Studi di Ferrara (UniFE), McMaster University [Hamilton, Ontario], Brigham & Women’s Hospital [Boston] (BWH), Harvard Medical School [Boston] (HMS), INSERM U1059, SAINBIOSE - Santé, Ingénierie, Biologie, Saint-Etienne (SAINBIOSE-ENSMSE), Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Ingénierie et Santé (CIS-ENSMSE), École des Mines de Saint-Étienne (Mines Saint-Étienne MSE), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-École des Mines de Saint-Étienne (Mines Saint-Étienne MSE), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT), Universidad de Alcalá - University of Alcalá (UAH), Service de rhumatologie [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), University of Otago [Dunedin, Nouvelle-Zélande], Université de Lille, Technische Hochschule Mittelhessen - University of Applied Sciences [Giessen] (THM), University of Queensland [Brisbane], University College of London [London] (UCL), Repositório da Universidade de Lisboa, University of California (UC), Universidade de Lisboa = University of Lisbon (ULISBOA), Università degli Studi di Ferrara = University of Ferrara (UniFE), Santé Ingénierie Biologie Saint-Etienne (SAINBIOSE), Centre Ingénierie et Santé (CIS-ENSMSE), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Strangfeld, A, Schafer, M, Gianfrancesco, M, Lawson-Tovey, S, Liew, J, Ljung, L, Mateus, E, Richez, C, Santos, M, Schmajuk, G, Scire, C, Sirotich, E, Sparks, J, Sufka, P, Thomas, T, Trupin, L, Wallace, Z, Al-Adely, S, Bachiller-Corral, J, Bhana, S, Cacoub, P, Carmona, L, Costello, R, Costello, W, Gossec, L, Grainger, R, Hachulla, E, Hasseli, R, Hausmann, J, Hyrich, K, Izadi, Z, Jacobsohn, L, Katz, P, Kearsley-Fleet, L, Robinson, P, Yazdany, J, Machado, P, and HAL-SU, Gestionnaire

Subjects
Male, 0301 basic medicine, Aging, antirheumatic agents, Epidemiology, Azathioprine, Comorbidity, Disease, Global Health, Cardiovascular, 0302 clinical medicine, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Odds Ratio, Immunology and Allergy, Registries, AcademicSubjects/MED00360, [SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases, [SDV.MHEP.RSOA] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, glucocorticoids, Middle Aged, health care, 3. Good health, [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, Letter to the Editor (Other), 6.1 Pharmaceuticals, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Public Health and Health Services, Female, epidemiology, Rituximab, medicine.drug, medicine.medical_specialty, Clinical Sciences, Immunology, autoimmune disease, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Autoimmune Disease, General Biochemistry, Genetics and Molecular Biology, Antibodies, Antineutrophil Cytoplasmic, 03 medical and health sciences, Rheumatology, Sulfasalazine, Rheumatic Diseases, Internal medicine, medicine, Humans, autoimmune diseases, outcome assessment, Aged, Rheumatology and Autoimmunity, 030203 arthritis & rheumatology, Reumatologi och inflammation, SARS-CoV-2, business.industry, Arthritis, Evaluation of treatments and therapeutic interventions, COVID-19, Odds ratio, medicine.disease, Arthritis & Rheumatology, Good Health and Well Being, 030104 developmental biology, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, COVID-19 Global Rheumatology Alliance, antirheumatic agent, glucocorticoid, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business
Abstract

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ., Objectives: To determine factors associated with COVID-19-related death in people with rheumatic diseases. Methods: Physician-reported registry of adults with rheumatic disease and confirmed or presumptive COVID-19 (from 24 March to 1 July 2020). The primary outcome was COVID-19-related death. Age, sex, smoking status, comorbidities, rheumatic disease diagnosis, disease activity and medications were included as covariates in multivariable logistic regression models. Analyses were further stratified according to rheumatic disease category. Results: Of 3729 patients (mean age 57 years, 68% female), 390 (10.5%) died. Independent factors associated with COVID-19-related death were age (66-75 years: OR 3.00, 95% CI 2.13 to 4.22; >75 years: 6.18, 4.47 to 8.53; both vs ≤65 years), male sex (1.46, 1.11 to 1.91), hypertension combined with cardiovascular disease (1.89, 1.31 to 2.73), chronic lung disease (1.68, 1.26 to 2.25) and prednisolone-equivalent dosage >10 mg/day (1.69, 1.18 to 2.41; vs no glucocorticoid intake). Moderate/high disease activity (vs remission/low disease activity) was associated with higher odds of death (1.87, 1.27 to 2.77). Rituximab (4.04, 2.32 to 7.03), sulfasalazine (3.60, 1.66 to 7.78), immunosuppressants (azathioprine, cyclophosphamide, ciclosporin, mycophenolate or tacrolimus: 2.22, 1.43 to 3.46) and not receiving any disease-modifying anti-rheumatic drug (DMARD) (2.11, 1.48 to 3.01) were associated with higher odds of death, compared with methotrexate monotherapy. Other synthetic/biological DMARDs were not associated with COVID-19-related death. Conclusion: Among people with rheumatic disease, COVID-19-related death was associated with known general factors (older age, male sex and specific comorbidities) and disease-specific factors (disease activity and specific medications). The association with moderate/high disease activity highlights the importance of adequate disease control with DMARDs, preferably without increasing glucocorticoid dosages. Caution may be required with rituximab, sulfasalazine and some immunosuppressants.

Published
2021

59. Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments

Author

Ferri, Clodoveo, primary, Giuggioli, Dilia, additional, Raimondo, Vincenzo, additional, L’Andolina, Massimo, additional, Dagna, Lorenzo, additional, Tavoni, Antonio, additional, Caso, Francesco, additional, Ursini, Francesco, additional, Ruscitti, Piero, additional, Caminiti, Maurizio, additional, Foti, Rosario, additional, Riccieri, Valeria, additional, Guiducci, Serena, additional, Pellegrini, Roberta, additional, Zanatta, Elisabetta, additional, Varcasia, Giuseppe, additional, Olivo, Domenico, additional, Gigliotti, Pietro, additional, Cuomo, Giovanna, additional, Murdaca, Giuseppe, additional, Cecchetti, Riccardo, additional, De Angelis, Rossella, additional, Romeo, Nicoletta, additional, Ingegnoli, Francesca, additional, Cozzi, Franco, additional, Codullo, Veronica, additional, Cavazzana, Ilaria, additional, Colaci, Michele, additional, Abignano, Giuseppina, additional, De Santis, Maria, additional, Lubrano, Ennio, additional, Fusaro, Enrico, additional, Rossa, Alessandra Della, additional, Spinella, Amelia, additional, Lumetti, Federica, additional, De Luca, Giacomo, additional, Bellando-Randone, Silvia, additional, Visalli, Elisa, additional, Dal Bosco, Ylenia, additional, Amato, Giorgio, additional, Giannini, Daiana, additional, Bilia, Silvia, additional, Masini, Francesco, additional, Pellegrino, Greta, additional, Pigatto, Erika, additional, Generali, Elena, additional, Mariano, Giuseppa Pagano, additional, Pettiti, Giorgio, additional, Zanframundo, Giovanni, additional, Brittelli, Raffaele, additional, Aiello, Vincenzo, additional, Caminiti, Rodolfo, additional, Scorpiniti, Daniela, additional, Ferrari, Tommaso, additional, Campochiaro, Corrado, additional, Brusi, Veronica, additional, Fredi, Micaela, additional, Moschetti, Liala, additional, Cacciapaglia, Fabio, additional, Gragnani, Laura, additional, Monti, Monica, additional, Lorini, Serena, additional, Paparo, Sabrina Rosaria, additional, Ragusa, Francesca, additional, Mazzi, Valeria, additional, Elia, Giusy, additional, Ferrari, Silvia Martina, additional, Di Cola, Ilenia, additional, Vadacca, Marta, additional, Lorusso, Sebastiano, additional, Barsotti, Simone, additional, Aprile, Maria Letizia, additional, Marco, Tasso, additional, Miccoli, Mario, additional, Bosello, Silvia, additional, Matucci-Cerinic, Marco, additional, D'Angelo, Salvatore, additional, Doria, Andrea, additional, Franceschini, Franco, additional, Meliconi, Riccardo, additional, Iannone, Florenzo, additional, Giacomelli, Roberto, additional, Zignego, Anna Linda, additional, Fallahi, Poupak, additional, and Antonelli, Alessandro, additional

Published
2021
Full Text
View/download PDF

60. Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort

Author

Gatto, Mariele, primary, Saccon, Francesca, additional, Andreoli, Laura, additional, Bartoloni, Elena, additional, Benvenuti, Francesco, additional, Bortoluzzi, Alessandra, additional, Bozzolo, Enrica, additional, Brunetta, Enrico, additional, Canti, Valentina, additional, Cardinaletti, Paolo, additional, Ceccarelli, Fulvia, additional, Ciccia, Francesco, additional, Conti, Fabrizio, additional, De Marchi, Ginevra, additional, de Paulis, Amato, additional, De Vita, Salvatore, additional, Emmi, Giacomo, additional, Faggioli, Paola, additional, Fasano, Serena, additional, Fredi, Micaela, additional, Gabrielli, Armando, additional, Gasparotto, Michela, additional, Gerli, Roberto, additional, Gerosa, Maria, additional, Govoni, Marcello, additional, Gremese, Elisa, additional, Laria, Antonella, additional, Larosa, Maddalena, additional, Mosca, Marta, additional, Orsolini, Giovanni, additional, Pazzola, Giulia, additional, Petricca, Luca, additional, Ramirez, Giuseppe A., additional, Regola, Francesca, additional, Rossi, Francesca W., additional, Rossini, Maurizio, additional, Salvarani, Carlo, additional, Scarpato, Salvatore, additional, Tani, Chiara, additional, Tincani, Angela, additional, Ubiali, Tania, additional, Urban, Maria Letizia, additional, Zen, Margherita, additional, Doria, Andrea, additional, and Iaccarino, Luca, additional

Published
2021
Full Text
View/download PDF

61. Similarities and differences between younger and older disease onset patients with newly diagnosed systemic lupus erythematosus

Author

Prevete, Immacolata, primary, Iuliano, Annamaria, additional, Cauli, Alberto, additional, Piga, Matteo, additional, Iannone, Florenzo, additional, Coladonato, Laura, additional, Bortoluzzi, Alessandra, additional, Silvagni, Ettore, additional, Tani, Chiara, additional, Elefante, Elena, additional, Doria, Andrea, additional, Iaccarino, Luca, additional, Franceschini, Franco, additional, Fredi, Micaela, additional, Conti, Fabrizio, additional, Spinelli, Francesca Romana, additional, Frediani, Bruno, additional, Gonzales Garcìa, Estrela, additional, Scirè, Carlo A, additional, Zanetti, Anna, additional, Rozza, Davide, additional, Carrara, Greta, additional, and Sebastiani, Gian Domenico, additional

Published
2021
Full Text
View/download PDF

65. Low Preconception Complement Levels Are Associated with Adverse Pregnancy Outcomes in a Multicenter Study of 260 Pregnancies in 197 Women with Antiphospholipid Syndrome or Carriers of Antiphospholipid Antibodies

Author

Nalli, Cecilia, primary, Lini, Daniele, additional, Andreoli, Laura, additional, Crisafulli, Francesca, additional, Fredi, Micaela, additional, Lazzaroni, Maria Grazia, additional, Bitsadze, Viktoria, additional, Calligaro, Antonia, additional, Canti, Valentina, additional, Caporali, Roberto, additional, Carubbi, Francesco, additional, Chighizola, Cecilia Beatrice, additional, Conigliaro, Paola, additional, Conti, Fabrizio, additional, De Carolis, Caterina, additional, Del Ross, Teresa, additional, Favaro, Maria, additional, Gerosa, Maria, additional, Iuliano, Annamaria, additional, Khizroeva, Jamilya, additional, Makatsariya, Alexander, additional, Meroni, Pier Luigi, additional, Mosca, Marta, additional, Padovan, Melissa, additional, Perricone, Roberto, additional, Rovere-Querini, Patrizia, additional, Sebastiani, Gian Domenico, additional, Tani, Chiara, additional, Tonello, Marta, additional, Truglia, Simona, additional, Zucchi, Dina, additional, Franceschini, Franco, additional, and Tincani, Angela, additional

Published
2021
Full Text
View/download PDF

66. Increased COVID-19 mortality in patients with rheumatic diseases: results from the CONTROL-19 study by the Italian Society for Rheumatology

Author

Zanetti, Anna, primary, Carrara, Greta, additional, Landolfi, Gianpiero, additional, Rozza, Davide, additional, Chighizola, Cecilia Beatrice, additional, Alunno, Alessia, additional, Andreoli, Laura, additional, Caporali, Roberto, additional, Gerli, Roberto, additional, Sebastiani, Gian Domenico, additional, Valesini, Guido, additional, Sinigaglia, Luigi, additional, Raffeiner, Bernd, additional, Lomater, Claudia, additional, Caprioli, Marta, additional, Fredi, Micaela, additional, Romeo, Nicoletta, additional, Cuomo, Giovanna, additional, Vadacca, Marta, additional, and Scirè, Carlo Alberto, additional

Published
2021
Full Text
View/download PDF

67. Serum IgG2 antibody multi-composition in systemic lupus erythematosus and in lupus nephritis (Part 2): prospective study

Author

Bruschi, M, Moroni, G, Sinico, R, Franceschini, F, Fredi, M, Vaglio, A, Cavagna, L, Petretto, A, Pratesi, F, Migliorini, P, Locatelli, F, Pazzola, G, Pesce, G, Bagnasco, M, Manfredi, A, Ramirez, G, Esposito, P, Murdaca, G, Negrini, S, Cipriani, L, Trezzi, B, Emmi, G, Cavazzana, I, Binda, V, D'Alessandro, M, Fenaroli, P, Pisani, I, Garibotto, G, Montecucco, C, Santoro, D, Scolari, F, Volpi, S, Mosca, M, Tincani, A, Candiano, G, Prunotto, M, Verrina, E, Angeletti, A, Ravelli, A, Ghiggeri, G, Bruschi, Maurizio, Moroni, Gabriella, Sinico, Renato Alberto, Franceschini, Franco, Fredi, Micaela, Vaglio, Augusto, Cavagna, Lorenzo, Petretto, Andrea, Pratesi, Federico, Migliorini, Paola, Locatelli, Francesco, Pazzola, Giulia, Pesce, Giampaola, Bagnasco, Marcello, Manfredi, Angelo, Ramirez, Giuseppe A, Esposito, Pasquale, Murdaca, Giuseppe, Negrini, Simone, Cipriani, Leda, Trezzi, Barbara, Emmi, Giacomo, Cavazzana, Ilaria, Binda, Valentina, d'Alessandro, Matteo, Fenaroli, Paride, Pisani, Isabella, Garibotto, Giacomo, Montecucco, Carlomaurizio, Santoro, Domenico, Scolari, Francesco, Volpi, Stefano, Mosca, Marta, Tincani, Angela, Candiano, Giovanni, Prunotto, Marco, Verrina, Enrico, Angeletti, Andrea, Ravelli, Angelo, Ghiggeri, Gian Marco, Bruschi, M, Moroni, G, Sinico, R, Franceschini, F, Fredi, M, Vaglio, A, Cavagna, L, Petretto, A, Pratesi, F, Migliorini, P, Locatelli, F, Pazzola, G, Pesce, G, Bagnasco, M, Manfredi, A, Ramirez, G, Esposito, P, Murdaca, G, Negrini, S, Cipriani, L, Trezzi, B, Emmi, G, Cavazzana, I, Binda, V, D'Alessandro, M, Fenaroli, P, Pisani, I, Garibotto, G, Montecucco, C, Santoro, D, Scolari, F, Volpi, S, Mosca, M, Tincani, A, Candiano, G, Prunotto, M, Verrina, E, Angeletti, A, Ravelli, A, Ghiggeri, G, Bruschi, Maurizio, Moroni, Gabriella, Sinico, Renato Alberto, Franceschini, Franco, Fredi, Micaela, Vaglio, Augusto, Cavagna, Lorenzo, Petretto, Andrea, Pratesi, Federico, Migliorini, Paola, Locatelli, Francesco, Pazzola, Giulia, Pesce, Giampaola, Bagnasco, Marcello, Manfredi, Angelo, Ramirez, Giuseppe A, Esposito, Pasquale, Murdaca, Giuseppe, Negrini, Simone, Cipriani, Leda, Trezzi, Barbara, Emmi, Giacomo, Cavazzana, Ilaria, Binda, Valentina, d'Alessandro, Matteo, Fenaroli, Paride, Pisani, Isabella, Garibotto, Giacomo, Montecucco, Carlomaurizio, Santoro, Domenico, Scolari, Francesco, Volpi, Stefano, Mosca, Marta, Tincani, Angela, Candiano, Giovanni, Prunotto, Marco, Verrina, Enrico, Angeletti, Andrea, Ravelli, Angelo, and Ghiggeri, Gian Marco

Abstract

Objectives: Circulating anti-ENO1 and anti-H2A IgG2 have been identified as specific signatures of LN in a cross-over approach. We sought to show whether the same antibodies identify selected population of patients with LN with potentially different clinical outcomes. Methods: Here we report the prospective analysis over 36 months of circulating IgG2 levels in patients with newly diagnosed LN (n=91) and SLE (n=31) and in other patients with SLE recruited within 2 years from diagnosis (n=99). Anti-podocyte (ENO1), anti-nucleosome (DNA, histone 2 A, histone 3) and anti-circulating proteins (C1q, AnnexinA1-ANXA1) IgG2 antibodies were determined by home-made techniques. Results: LN patients were the main focus of the study. Anti-ENO1, anti-H2A and anti-ANXA1 IgG2 decreased in parallel to proteinuria and normalized within 12 months in the majority of patients while anti-dsDNA IgG2 remained high over the 36 months. Anti-ENO1 and anti-H2A had the highest association with proteinuria (Heat Map) and identified the highest number of patients with high proteinuria (68% and 71% respectively) and/or with reduced estimated glomerula filtration rate (eGFR) (58% for both antibodies) compared with 23% and 17% of anti-dsDNA (agreement analysis). Anti-ENO1 positive LN patients had higher proteinuria than negative patients at T0 and presented the maximal decrement within 12 months. Conclusions: Anti-ENO1, anti-H2A and anti-ANXA1 antibodies were associated with high proteinuria in LN patients and Anti-ENO1 also presented the maximal reduction within 12 months that paralleled the decrease of proteinuria. Anti-dsDNA were not associated with renal outcome parameters. New IgG2 antibody signatures should be utilized as tracers of personalized therapies in LN. Trial registration: The Zeus study was registered at https://clinicaltrials.gov (study number: NCT02403115).

Published
2021

68. Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments

Author

Ferri, Clodoveo, Giuggioli, Dilia, Raimondo, Vincenzo, L'Andolina, Massimo, Dagna, Lorenzo, Tavoni, Antonio, Caso, Francesco, Ursini, Francesco, Ruscitti, Piero, Caminiti, Maurizio, Foti, Rosario, Riccieri, Valeria, Guiducci, Serena, Pellegrini, Roberta, Zanatta, Elisabetta, Varcasia, Giuseppe, Olivo, Domenico, Gigliotti, Pietro, Cuomo, Giovanna, Murdaca, Giuseppe, Cecchetti, Riccardo, De Angelis, Rossella, Romeo, Nicoletta, Ingegnoli, Francesca, Cozzi, Franco, Codullo, Veronica, Cavazzana, Ilaria, Colaci, Michele, Abignano, Giuseppina, De Santis, Maria, Lubrano, Ennio, Fusaro, Enrico, Rossa, Alessandra Della, Spinella, Amelia, Lumetti, Federica, De Luca, Giacomo, Bellando-Randone, Silvia, Visalli, Elisa, Dal Bosco, Ylenia, Amato, Giorgio, Giannini, Daiana, Bilia, Silvia, Masini, Francesco, Pellegrino, Greta, Pigatto, Erika, Generali, Elena, Mariano, Giuseppa Pagano, Pettiti, Giorgio, Zanframundo, Giovanni, Brittelli, Raffaele, Aiello, Vincenzo, Caminiti, Rodolfo, Scorpiniti, Daniela, Ferrari, Tommaso, Campochiaro, Corrado, Brusi, Veronica, Fredi, Micaela, Moschetti, Liala, Cacciapaglia, Fabio, Gragnani, Laura, Monti, Monica, Lorini, Serena, Paparo, Sabrina Rosaria, Ragusa, Francesca, Mazzi, Valeria, Elia, Giusy, Ferrari, Silvia Martina, Di Cola, Ilenia, Vadacca, Marta, Lorusso, Sebastiano, Barsotti, Simone, Aprile, Maria Letizia, Marco, Tasso, Miccoli, Mario, Bosello, Silvia Laura, Matucci-Cerinic, Marco, D'Angelo, Salvatore, Doria, Andrea, Franceschini, Franco, Meliconi, Riccardo, Iannone, Florenzo, Giacomelli, Roberto, Zignego, Anna Linda, Fallahi, Poupak, Antonelli, Alessandro, Bosello, Silvia (ORCID:0000-0002-4837-447X), Ferri, Clodoveo, Giuggioli, Dilia, Raimondo, Vincenzo, L'Andolina, Massimo, Dagna, Lorenzo, Tavoni, Antonio, Caso, Francesco, Ursini, Francesco, Ruscitti, Piero, Caminiti, Maurizio, Foti, Rosario, Riccieri, Valeria, Guiducci, Serena, Pellegrini, Roberta, Zanatta, Elisabetta, Varcasia, Giuseppe, Olivo, Domenico, Gigliotti, Pietro, Cuomo, Giovanna, Murdaca, Giuseppe, Cecchetti, Riccardo, De Angelis, Rossella, Romeo, Nicoletta, Ingegnoli, Francesca, Cozzi, Franco, Codullo, Veronica, Cavazzana, Ilaria, Colaci, Michele, Abignano, Giuseppina, De Santis, Maria, Lubrano, Ennio, Fusaro, Enrico, Rossa, Alessandra Della, Spinella, Amelia, Lumetti, Federica, De Luca, Giacomo, Bellando-Randone, Silvia, Visalli, Elisa, Dal Bosco, Ylenia, Amato, Giorgio, Giannini, Daiana, Bilia, Silvia, Masini, Francesco, Pellegrino, Greta, Pigatto, Erika, Generali, Elena, Mariano, Giuseppa Pagano, Pettiti, Giorgio, Zanframundo, Giovanni, Brittelli, Raffaele, Aiello, Vincenzo, Caminiti, Rodolfo, Scorpiniti, Daniela, Ferrari, Tommaso, Campochiaro, Corrado, Brusi, Veronica, Fredi, Micaela, Moschetti, Liala, Cacciapaglia, Fabio, Gragnani, Laura, Monti, Monica, Lorini, Serena, Paparo, Sabrina Rosaria, Ragusa, Francesca, Mazzi, Valeria, Elia, Giusy, Ferrari, Silvia Martina, Di Cola, Ilenia, Vadacca, Marta, Lorusso, Sebastiano, Barsotti, Simone, Aprile, Maria Letizia, Marco, Tasso, Miccoli, Mario, Bosello, Silvia Laura, Matucci-Cerinic, Marco, D'Angelo, Salvatore, Doria, Andrea, Franceschini, Franco, Meliconi, Riccardo, Iannone, Florenzo, Giacomelli, Roberto, Zignego, Anna Linda, Fallahi, Poupak, Antonelli, Alessandro, and Bosello, Silvia (ORCID:0000-0002-4837-447X)

Abstract

Background: The Covid-19 pandemic may have a deleterious impact on patients with autoimmune systemic diseases (ASD) due to their deep immune-system alterations. Objective: This study aims to investigate the prevalence of symptomatic Covid-19 and its correlations with both organ involvement and ongoing treatments in a large series of Italian ASD patients during the first wave of pandemic. Methods: Our multicenter telephone 6-week survey included 3,029 unselected ASD patients enrolled at 36 tertiary referral centers of northern, central, and southern Italian macro-areas with different diffusion of the pandemic. Symptomatic SARS-CoV-2 infection was classified as definite Covid-19 (presence of symptoms plus positive oral/nasopharyngeal swabs) or highly suspected Covid-19 (highly suggestive symptoms, in the absence of a swab testing). Results: A significantly higher prevalence of definite plus highly suspected Covid-19 compared to the Italian general population was detected in the whole ASD series (p=.000), as well as in patients from the three macro-areas (p=.000 in all). Statistically higher prevalence of Covid-19 was also found in connective tissue diseases compared to chronic arthritis subgroup (p=.000) and in ASD patients with pre-existing interstitial lung involvement (p=.000). Patients treated with either conventional disease-modifying anti-rheumatic drugs (DMARDs) and/or biological DMARDs showed a significantly lower prevalence of Covid-19 (p=.000 in both). Finally, scleroderma patients undergoing low-dose aspirin showed a significantly lower rate of Covid-19 compared to those without (p=0.003). Conclusion: The higher prevalence of Covid-19 in ASD patients, along with the significant correlations with important clinical features and therapeutic regimens, suggests the need to develop targeted prevention/management strategies during the current pandemic wave.

Published
2021

69. Second wave antibodies in autoimmune renal diseases: The case of lupus nephritis

Author

Angeletti, A, Bruschi, M, Moroni, G, Sinico, R, Franceschini, F, Fredi, M, Vaglio, A, Cavagna, L, Petretto, A, Pratesi, F, Migliorini, P, Locatelli, F, Pazzola, G, Pesce, G, Bagnasco, M, Manfredi, A, Ramirez, G, Esposito, P, Murdaca, G, Negrini, S, Cipriani, L, Trezzi, B, Emmi, G, Cavazzana, I, Binda, V, D'Alessandro, M, Fenaroli, P, Pisani, I, Garibotto, G, Montecucco, C, Santoro, D, Scolari, F, Volpi, S, Mosca, M, Tincani, A, Candiano, G, Prunotto, M, Verrina, E, Ravelli, A, Ghiggeri, G, Angeletti, Andrea, Bruschi, Maurizio, Moroni, Gabriela, Sinico, Renato, Franceschini, Franco, Fredi, Micaela, Vaglio, Augusto, Cavagna, Lorenzo, Petretto, Andrea, Pratesi, Federico, Migliorini, Paola, Locatelli, Francesco, Pazzola, Giulia, Pesce, Giampaola, Bagnasco, Marcello, Manfredi, Angelo, Ramirez, Giuseppe, Esposito, Pasquale, Murdaca, Giuseppe, Negrini, Simone, Cipriani, Leda, Trezzi, Barbara, Emmi, Giacomo, Cavazzana, Ilaria, Binda, Valentina, d'Alessandro, Matteo, Fenaroli, Paride, Pisani, Isabella, Garibotto, Giacomo, Montecucco, Carlomaurizio, Santoro, Domenico, Scolari, Francesco, Volpi, Stefano, Mosca, Marta, Tincani, Angela, Candiano, Giovanni, Prunotto, Marco, Verrina, Enrico, Ravelli, Angelo, Ghiggeri, Gian Marco, Angeletti, A, Bruschi, M, Moroni, G, Sinico, R, Franceschini, F, Fredi, M, Vaglio, A, Cavagna, L, Petretto, A, Pratesi, F, Migliorini, P, Locatelli, F, Pazzola, G, Pesce, G, Bagnasco, M, Manfredi, A, Ramirez, G, Esposito, P, Murdaca, G, Negrini, S, Cipriani, L, Trezzi, B, Emmi, G, Cavazzana, I, Binda, V, D'Alessandro, M, Fenaroli, P, Pisani, I, Garibotto, G, Montecucco, C, Santoro, D, Scolari, F, Volpi, S, Mosca, M, Tincani, A, Candiano, G, Prunotto, M, Verrina, E, Ravelli, A, Ghiggeri, G, Angeletti, Andrea, Bruschi, Maurizio, Moroni, Gabriela, Sinico, Renato, Franceschini, Franco, Fredi, Micaela, Vaglio, Augusto, Cavagna, Lorenzo, Petretto, Andrea, Pratesi, Federico, Migliorini, Paola, Locatelli, Francesco, Pazzola, Giulia, Pesce, Giampaola, Bagnasco, Marcello, Manfredi, Angelo, Ramirez, Giuseppe, Esposito, Pasquale, Murdaca, Giuseppe, Negrini, Simone, Cipriani, Leda, Trezzi, Barbara, Emmi, Giacomo, Cavazzana, Ilaria, Binda, Valentina, d'Alessandro, Matteo, Fenaroli, Paride, Pisani, Isabella, Garibotto, Giacomo, Montecucco, Carlomaurizio, Santoro, Domenico, Scolari, Francesco, Volpi, Stefano, Mosca, Marta, Tincani, Angela, Candiano, Giovanni, Prunotto, Marco, Verrina, Enrico, Ravelli, Angelo, and Ghiggeri, Gian Marco

Abstract

Clinical Trial registry name and registration number: Zeus study, NCT02403115

Published
2021

70. Neutrophil Extracellular Traps in the Autoimmunity Context

Author

Bruschi, M, Moroni, G, Sinico, R, Franceschini, F, Fredi, M, Vaglio, A, Cavagna, L, Petretto, A, Pratesi, F, Migliorini, P, Manfredi, A, Ramirez, G, Esposito, P, Negrini, S, Trezzi, B, Emmi, G, Santoro, D, Scolari, F, Volpi, S, Mosca, M, Tincani, A, Candiano, G, Prunotto, M, Verrina, E, Angeletti, A, Ravelli, A, Ghiggeri, G, Bruschi, Maurizio, Moroni, Gabriella, Sinico, Renato Alberto, Franceschini, Franco, Fredi, Micaela, Vaglio, Augusto, Cavagna, Lorenzo, Petretto, Andrea, Pratesi, Federico, Migliorini, Paola, Manfredi, Angelo, Ramirez, Giuseppe A., Esposito, Pasquale, Negrini, Simone, Trezzi, Barbara, Emmi, Giacomo, Santoro, Domenico, Scolari, Francesco, Volpi, Stefano, Mosca, Marta, Tincani, Angela, Candiano, Giovanni, Prunotto, Marco, Verrina, Enrico, Angeletti, Andrea, Ravelli, Angelo, Ghiggeri, Gian Marco, Bruschi, M, Moroni, G, Sinico, R, Franceschini, F, Fredi, M, Vaglio, A, Cavagna, L, Petretto, A, Pratesi, F, Migliorini, P, Manfredi, A, Ramirez, G, Esposito, P, Negrini, S, Trezzi, B, Emmi, G, Santoro, D, Scolari, F, Volpi, S, Mosca, M, Tincani, A, Candiano, G, Prunotto, M, Verrina, E, Angeletti, A, Ravelli, A, Ghiggeri, G, Bruschi, Maurizio, Moroni, Gabriella, Sinico, Renato Alberto, Franceschini, Franco, Fredi, Micaela, Vaglio, Augusto, Cavagna, Lorenzo, Petretto, Andrea, Pratesi, Federico, Migliorini, Paola, Manfredi, Angelo, Ramirez, Giuseppe A., Esposito, Pasquale, Negrini, Simone, Trezzi, Barbara, Emmi, Giacomo, Santoro, Domenico, Scolari, Francesco, Volpi, Stefano, Mosca, Marta, Tincani, Angela, Candiano, Giovanni, Prunotto, Marco, Verrina, Enrico, Angeletti, Andrea, Ravelli, Angelo, and Ghiggeri, Gian Marco

Abstract

The formation of neutrophil extracellular traps (NETs) is a strategy utilized by neutrophils for capturing infective agents. Extracellular traps consist in a physical net made of DNA and intracellular proteins externalized from neutrophils, where bacteria and viruses are entrapped and killed by proteolysis. A complex series of events contributes to achieving NET formation: signaling from infectious triggers comes first, followed by decondensation of chromatin and extrusion of the nucleosome components (DNA, histones) from the nucleus and, after cell membrane breakdown, outside the cell. NETs are composed of either DNA or nucleosome proteins and hundreds of cytoplasm proteins, a part of which undergo post-translational modification during the steps leading to NETs. There is a thin balance between the production and the removal of circulating NETs from blood where digestion of DNA by circulating DNases 1 and IL3 has a critical role. A delay in NET removal may have consequences for autoimmunity. Recent studies have shown that circulating NET levels are increased in systemic lupus erythematosus (SLE) for a functional block of NET removal mediated by anti-DNase antibodies or, in rare cases, by DNase IL3 mutations. In SLE, the persistence in circulation of NETs signifies elevated concentrations of either free DNA/nucleosome components and oxidized proteins that, in some cases, are recognized as non-self and presented to B-cells by Toll-like receptor 9 (TLR9). In this way, it is activated as an immunologic response, leading to the formation of IgG2 auto-antibody. Monitoring serum NET levels represents a potential new way to herald the development of renal lesions and has clinical implications. Modulating the balance between NET formation and removal is one of the objectives of basic research that are aimed to design new drugs for SLE. Clinical Trial Registration Number: The Zeus study was registered at https://clinicaltrials.gov (study number: NCT02403115).

Published
2021

71. Serum IgG2 antibody multicomposition in systemic lupus erythematosus and lupus nephritis (Part 1): cross-sectional analysis

Author

Bruschi, M, Moroni, G, Sinico, R, Franceschini, F, Fredi, M, Vaglio, A, Cavagna, L, Petretto, A, Pratesi, F, Migliorini, P, Locatelli, F, Pazzola, G, Pesce, G, Bagnasco, M, Manfredi, A, Ramirez, G, Esposito, P, Murdaca, G, Negrini, S, Cipriani, L, Trezzi, B, Emmi, G, Cavazzana, I, Binda, V, Fenaroli, P, Pisani, I, Garibotto, G, Montecucco, C, Santoro, D, Scolari, F, Mosca, M, Tincani, A, Candiano, G, Prunotto, M, Volpi, S, Verrina, E, Angeletti, A, Ravelli, A, Ghiggeri, G, Bruschi, Maurizio, Moroni, Gabriella, Sinico, Renato Alberto, Franceschini, Franco, Fredi, Micaela&nbsp, Vaglio, Augusto, Cavagna, Lorenzo, Petretto, Andrea, Pratesi, Federico, Migliorini, Paola, Locatelli, Francesco, Pazzola, Giulia, Pesce, Giampaola, Bagnasco, Marcello&nbsp, Manfredi, Angelo, Ramirez, Giuseppe A, Esposito, Pasquale, Murdaca, Giuseppe, Negrini, Simone, Cipriani, Leda, Trezzi, Barbara, Emmi, Giacomo, Cavazzana, Ilaria, Binda, Valentina, Fenaroli, Paride, Pisani, Isabella, Garibotto, Giacomo, Montecucco, Carlomaurizio, Santoro, Domenico, Scolari, Francesco, Mosca, Marta, Tincani, Angela&nbsp, Candiano, Giovanni, Prunotto, Marco, Volpi, Stefano, Verrina, Enrico, Angeletti, Andrea, Ravelli, Angelo, Ghiggeri, Gian Marco, Bruschi, M, Moroni, G, Sinico, R, Franceschini, F, Fredi, M, Vaglio, A, Cavagna, L, Petretto, A, Pratesi, F, Migliorini, P, Locatelli, F, Pazzola, G, Pesce, G, Bagnasco, M, Manfredi, A, Ramirez, G, Esposito, P, Murdaca, G, Negrini, S, Cipriani, L, Trezzi, B, Emmi, G, Cavazzana, I, Binda, V, Fenaroli, P, Pisani, I, Garibotto, G, Montecucco, C, Santoro, D, Scolari, F, Mosca, M, Tincani, A, Candiano, G, Prunotto, M, Volpi, S, Verrina, E, Angeletti, A, Ravelli, A, Ghiggeri, G, Bruschi, Maurizio, Moroni, Gabriella, Sinico, Renato Alberto, Franceschini, Franco, Fredi, Micaela&nbsp, Vaglio, Augusto, Cavagna, Lorenzo, Petretto, Andrea, Pratesi, Federico, Migliorini, Paola, Locatelli, Francesco, Pazzola, Giulia, Pesce, Giampaola, Bagnasco, Marcello&nbsp, Manfredi, Angelo, Ramirez, Giuseppe A, Esposito, Pasquale, Murdaca, Giuseppe, Negrini, Simone, Cipriani, Leda, Trezzi, Barbara, Emmi, Giacomo, Cavazzana, Ilaria, Binda, Valentina, Fenaroli, Paride, Pisani, Isabella, Garibotto, Giacomo, Montecucco, Carlomaurizio, Santoro, Domenico, Scolari, Francesco, Mosca, Marta, Tincani, Angela&nbsp, Candiano, Giovanni, Prunotto, Marco, Volpi, Stefano, Verrina, Enrico, Angeletti, Andrea, Ravelli, Angelo, and Ghiggeri, Gian Marco

Abstract

Objectives: Serum anti-dsDNA and anti-nucleosome IgGs have been proposed as signatures for SLE and LN in limited numbers of patients. We sought to show higher sensitivity and specificity of the same antibodies with the IgG2 isotype and included IgG2 antibodies vs specific intracellular antigens in the analysis. Methods: A total of 1052 SLE patients with (n = 479) and without (n = 573) LN, recruited at different times from the beginning of symptoms, were included in the study. Patients with primary APS (PAPS, n = 24), RA (RA, n = 24) and UCTD (UCTD, n = 96) were analysed for comparison. Anti-nucleosome (dsDNA, Histone2A, Histone3), anti-intracellular antigens (ENO1), anti-annexin A1 and anti-C1q IgG2 were determined by non-commercial techniques. Results: The presence in the serum of the IgG2 panel was highly discriminatory for SLE/LN vs healthy subjects. Serum levels of anti-dsDNA and anti-C1q IgG2 were more sensitive than those of IgGs (Farr radioimmunoassay/commercial assays) in identifying SLE patients at low-medium increments. Of more importance, serum positivity for anti-ENO1 and anti-H2A IgG2 discriminated between LN and SLE (ROC T0-12 months), and high levels at T0-1 month were detected in 63% and 67%, respectively, of LN, vs 3% and 3%, respectively, of SLE patients; serum positivity for each of these was correlated with high SLEDAI values. Minor differences existed between LN/SLE and the other rheumatologic conditions. Conclusion: Nephritogenic IgG2 antibodies represent a specific signature of SLE/LN, with a few overlaps with other rheumatologic conditions. High levels of anti-ENO1 and anti-H2A IgG2 correlated with SLE activity indexes and were discriminatory between SLE patients limited to the renal complication and other SLE patients. Trial registration: The Zeus study was registered at https://clinicaltrials.gov, NCT02403115.

Published
2021

72. Use of rituximab in a multicentre cohort of patients with rheumatic diseases during the outbreak of novel SARS-COV-2 infection

Author

Batticciotto, Alberto, primary, Marotto, Daniela, additional, Giorgi, Valeria, additional, Balzarini, Patrizia, additional, Favalli, Ennio Giulio, additional, Balduzzi, Silvia, additional, Fredi, Micaela, additional, Bazzani, Chiara, additional, Sartorelli, Silvia, additional, Ravagnani, Viviana, additional, Tamanini, Silvia, additional, Castelnovo, Laura, additional, Lurati, Alfredo Maria, additional, Farah, Sonia, additional, Bongiovanni, Sara, additional, Caporali, Roberto, additional, Dagna, Lorenzo, additional, Faggioli, Paola, additional, Franceschini, Franco, additional, Montecucco, Carlo Maurizio, additional, Salaffi, Fausto, additional, Galli, Massimo, additional, Cappelli, Antonella, additional, and Sarzi-Puttini, Piercarlo, additional

Published
2021
Full Text
View/download PDF

74. Neutrophil Extracellular Traps in the Autoimmunity Context

Author

Bruschi, Maurizio, primary, Moroni, Gabriella, additional, Sinico, Renato Alberto, additional, Franceschini, Franco, additional, Fredi, Micaela, additional, Vaglio, Augusto, additional, Cavagna, Lorenzo, additional, Petretto, Andrea, additional, Pratesi, Federico, additional, Migliorini, Paola, additional, Manfredi, Angelo, additional, Ramirez, Giuseppe A., additional, Esposito, Pasquale, additional, Negrini, Simone, additional, Trezzi, Barbara, additional, Emmi, Giacomo, additional, Santoro, Domenico, additional, Scolari, Francesco, additional, Volpi, Stefano, additional, Mosca, Marta, additional, Tincani, Angela, additional, Candiano, Giovanni, additional, Prunotto, Marco, additional, Verrina, Enrico, additional, Angeletti, Andrea, additional, Ravelli, Angelo, additional, and Ghiggeri, Gian Marco, additional

Published
2021
Full Text
View/download PDF

76. Serum IgG2 antibody multicomposition in systemic lupus erythematosus and lupus nephritis (Part 1): cross-sectional analysis

Author

Bruschi, Maurizio, primary, Moroni, Gabriella, additional, Sinico, Renato Alberto, additional, Franceschini, Franco, additional, Fredi, Micaela , additional, Vaglio, Augusto, additional, Cavagna, Lorenzo, additional, Petretto, Andrea, additional, Pratesi, Federico, additional, Migliorini, Paola, additional, Locatelli, Francesco, additional, Pazzola, Giulia, additional, Pesce, Giampaola, additional, Bagnasco, Marcello , additional, Manfredi, Angelo, additional, Ramirez, Giuseppe A, additional, Esposito, Pasquale, additional, Murdaca, Giuseppe, additional, Negrini, Simone, additional, Cipriani, Leda, additional, Trezzi, Barbara, additional, Emmi, Giacomo, additional, Cavazzana, Ilaria, additional, Binda, Valentina, additional, Fenaroli, Paride, additional, Pisani, Isabella, additional, Garibotto, Giacomo, additional, Montecucco, Carlomaurizio, additional, Santoro, Domenico, additional, Scolari, Francesco, additional, Mosca, Marta, additional, Tincani, Angela , additional, Candiano, Giovanni, additional, Prunotto, Marco, additional, Volpi, Stefano, additional, Verrina, Enrico, additional, Angeletti, Andrea, additional, Ravelli, Angelo, additional, and Ghiggeri, Gian Marco, additional

Published
2020
Full Text
View/download PDF

77. Serum IgG2 antibody multi-composition in systemic lupus erythematosus and in lupus nephritis (Part 2): prospective study

Author

Bruschi, Maurizio, primary, Moroni, Gabriella, additional, Sinico, Renato Alberto, additional, Franceschini, Franco, additional, Fredi, Micaela, additional, Vaglio, Augusto, additional, Cavagna, Lorenzo, additional, Petretto, Andrea, additional, Pratesi, Federico, additional, Migliorini, Paola, additional, Locatelli, Francesco, additional, Pazzola, Giulia, additional, Pesce, Giampaola, additional, Bagnasco, Marcello, additional, Manfredi, Angelo, additional, Ramirez, Giuseppe A, additional, Esposito, Pasquale, additional, Murdaca, Giuseppe, additional, Negrini, Simone, additional, Cipriani, Leda, additional, Trezzi, Barbara, additional, Emmi, Giacomo, additional, Cavazzana, Ilaria, additional, Binda, Valentina, additional, d’Alessandro, Matteo, additional, Fenaroli, Paride, additional, Pisani, Isabella, additional, Garibotto, Giacomo, additional, Montecucco, Carlomaurizio, additional, Santoro, Domenico, additional, Scolari, Francesco, additional, Volpi, Stefano, additional, Mosca, Marta, additional, Tincani, Angela, additional, Candiano, Giovanni, additional, Prunotto, Marco, additional, Verrina, Enrico, additional, Angeletti, Andrea, additional, Ravelli, Angelo, additional, and Ghiggeri, Gian Marco, additional

Published
2020
Full Text
View/download PDF

78. Inherited thrombophilia in women with poor aPL-related obstetric history: prevalence and outcomes. Survey of 208 cases from the European Registry on Obstetric Antiphospholipid Syndrome cohort

Author

Alijotas Reig, Jaume, Ferrer Oliveras, Raquel, Esteve Valverde, Enrique, Ruffatti, Amelia, Tincani, Angela, Lefkou, Elmina, Bertero, Maria Tiziana, Espinosa, Gerard, Coloma, Emmanuel, de Carolis, Sara, Rovere Querini, Patrizia, Canti, Valentina, Picardo, Elisa, Fredi, Micaela, Mekinian, Arsene, Kuzenko, Anna, Ruano, Anna, del Ross, Teresa, Melnychuk, Taisiia, Lundelin, Krista, Llurba, Elisa, Cervera, Ricard, Toth, Bettina, Saez Comet, Luis, Bremme, Katharina, Mayer Pickel, Karoline, Gil Aguado, Antonio, Alijotas-Reig, Jaume, Ferrer-Oliveras, Raquel, Esteve-Valverde, Enrique, Ruffatti, Amelia, Tincani, Angela, Lefkou, Elmina, Bertero, Maria Tiziana, Espinosa, Gerard, Coloma, Emmanuel, de Carolis, Sara, Rovere-Querini, Patrizia, Canti, Valentina, Picardo, Elisa, Fredi, Micaela, Mekinian, Arsene, and for the EUROAPS Study Group

Subjects
Adult, Pediatrics, medicine.medical_specialty, antiphospholipid antibody, inherited thrombophilia, obstetric outcome, thrombosis, treatment, Immunology and Allergy, Immunology, Reproductive Medicine, Obstetrics and Gynecology, 030204 cardiovascular system & hematology, 03 medical and health sciences, 0302 clinical medicine, Pregnancy, immune system diseases, Antiphospholipid syndrome, Prevalence, Humans, Thrombophilia, thrombosi, Medicine, Registries, Inherited thrombophilia, 030203 arthritis & rheumatology, Thrombotic risk, business.industry, Pregnancy Complications, Hematologic, Pregnancy Outcome, Antiphospholipid Syndrome, medicine.disease, Thrombosis, Europe, body regions, Obstetric history, Cohort, Female, Registry data, business, psychological phenomena and processes
Abstract

Aim To analyse the prevalence and effects of inherited thrombophilic disorders (ITD) on maternal-foetal outcomes in cases of antiphospholipid antibody related to obstetric complications. Methods Women with obstetric complaints who tested positive for aPL and with inherited thrombophilia were prospectively and retrospectively included. Results ITD data were available in 208 of 338: 147 had obstetric antiphospholipid syndrome (OAPS) and 61 aPL-related obstetric morbidity (OMAPS). 24.1% had ITD. Laboratory categories I and IIa were more related to OAPS-ITD and IIb and IIc to OMAPS-ITD. No significant differences in obstetric complaints were observed. Regarding ITD carriers, treatment rates were higher in OAPS than in OMAPS for LMWH and LDA plus LMWH (P=.002). Conclusion Cases with aPL-related OAPS/OMAPS showed no differences in maternal-foetal outcomes regardless of the presence of one ITD. Maternal thrombotic risk was low, with ITD-positive cases included. Registry data concur with Sydney criteria, whereby aPL-ITD-positive patients are classified as having antiphospholipid syndrome.

Published
2016

80. Severe muscle damage with myofiber necrosis and macrophage infiltrates characterize anti-Mi2 positive dermatomyositis

Author

Fornaro, Marco, primary, Girolamo, Francesco, additional, Cavagna, Lorenzo, additional, Franceschini, Franco, additional, Giannini, Margherita, additional, Amati, Angela, additional, Lia, Anna, additional, Tampoia, Marilina, additional, D’Abbicco, Dario, additional, Maggi, Lorenzo, additional, Fredi, Micaela, additional, Zanframundo, Giovanni, additional, Moschetti, Liala, additional, Coladonato, Laura, additional, and Iannone, Florenzo, additional

Published
2020
Full Text
View/download PDF

83. The IMMENSE Study: The Interplay Between iMMune and ENdothelial Cells in Mediating Cardiovascular Risk in Systemic Lupus Erythematosus

Author

Bortoluzzi, Alessandra, primary, Chighizola, Cecilia Beatrice, additional, Fredi, Micaela, additional, Raschi, Elena, additional, Bodio, Caterina, additional, Privitera, Daniela, additional, Gonelli, Arianna, additional, Silvagni, Ettore, additional, Govoni, Marcello, additional, Cavazzana, Ilaria, additional, Airò, Paolo, additional, Meroni, Pier Luigi, additional, Tincani, Angela, additional, Franceschini, Franco, additional, Piantoni, Silvia, additional, and Casciano, Fabio, additional

Published
2020
Full Text
View/download PDF

84. Disease course and obstetric outcomes of pregnancies in juvenile idiopathic arthritis: are there any differences among disease subtypes? A single-centre retrospective study of prospectively followed pregnancies in a dedicated pregnancy clinic

Author

García-Fernández, Antía, primary, Gerardi, Maria Chiara, additional, Crisafulli, Francesca, additional, Filippini, Matteo, additional, Fredi, Micaela, additional, Gorla, Roberto, additional, Lazzaroni, Maria Grazia, additional, Lojacono, Andrea, additional, Nalli, Cecilia, additional, Ramazzotto, Francesca, additional, Taglietti, Marco, additional, Zanardini, Cristina, additional, Zatti, Sonia, additional, Franceschini, Franco, additional, Tincani, Angela, additional, and Andreoli, Laura, additional

Published
2020
Full Text
View/download PDF

85. COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case–control study

Author

Fredi, Micaela, primary, Cavazzana, Ilaria, additional, Moschetti, Liala, additional, Andreoli, Laura, additional, Franceschini, Franco, additional, Airò, Paolo, additional, Bazzani, Chiara, additional, Crisafulli, Francesca, additional, Filippini, Matteo, additional, Frassi, Micol, additional, Gerardi, Maria Chiara, additional, Gorla, Roberto, additional, Lazzaroni, Maria Grazia, additional, Lini, Daniele, additional, Nalli, Cecilia, additional, Panaro, Salvatore, additional, Piantoni, Silvia, additional, Regola, Francesca, additional, Taglietti, Marco, additional, Tincani, Angela, additional, Toniati, Paola, additional, Vojinovic, Tamara, additional, and Zingarelli, Stefania, additional

Published
2020
Full Text
View/download PDF

86. Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real‐Life Setting

Author

Gatto, Mariele, primary, Saccon, Francesca, additional, Zen, Margherita, additional, Regola, Francesca, additional, Fredi, Micaela, additional, Andreoli, Laura, additional, Tincani, Angela, additional, Urban, Maria Letizia, additional, Emmi, Giacomo, additional, Ceccarelli, Fulvia, additional, Conti, Fabrizio, additional, Bortoluzzi, Alessandra, additional, Govoni, Marcello, additional, Tani, Chiara, additional, Mosca, Marta, additional, Ubiali, Tania, additional, Gerosa, Maria, additional, Bozzolo, Enrica, additional, Canti, Valentina, additional, Cardinaletti, Paolo, additional, Gabrielli, Armando, additional, Tanti, Giacomo, additional, Gremese, Elisa, additional, De Marchi, Ginevra, additional, De Vita, Salvatore, additional, Fasano, Serena, additional, Ciccia, Francesco, additional, Pazzola, Giulia, additional, Salvarani, Carlo, additional, Negrini, Simone, additional, Puppo, Francesco, additional, Di Matteo, Andrea, additional, De Angelis, Rossella, additional, Orsolini, Giovanni, additional, Rossini, Maurizio, additional, Faggioli, Paola, additional, Laria, Antonella, additional, Piga, Matteo, additional, Mathieu, Alessandro, additional, Scarpato, Salvatore, additional, Rossi, Francesca W., additional, Paulis, Amato, additional, Brunetta, Enrico, additional, Ceribelli, Angela, additional, Selmi, Carlo, additional, Prete, Marcella, additional, Racanelli, Vito, additional, Vacca, Angelo, additional, Bartoloni, Elena, additional, Gerli, Roberto, additional, Larosa, Maddalena, additional, Iaccarino, Luca, additional, and Doria, Andrea, additional

Published
2020
Full Text
View/download PDF

90. P75 Anti-SSA/Ro positivity and the risk of congenital heart block: obstetric and fetal outcome in a cohort of anti-SSA/Ro positive pregnant patients with and without autoimmune diseases

Author

Fredi, Micaela, primary, Gerosa, Maria, additional, Andreoli, Laura, additional, Vojanovic, Tamara, additional, Chighizola, Cecilia Beatrice, additional, Gazzola, Federica, additional, Lojacono, Andrea, additional, Zatti, Sonia, additional, Trespidi, Laura, additional, Ferrazzi, Enrico, additional, Caporali, Roberto, additional, Meroni, PierLuigi, additional, Franceschini, Franco, additional, and Tincani, Angela, additional

Published
2020
Full Text
View/download PDF

91. P74 Complement variations in systemic lupus erythematosus pregnancies

Author

Crisafulli, Francesca, primary, Andreoli, Laura, additional, Filippini, Matteo, additional, Fredi, Micaela, additional, Gerardi, Maria Chiara, additional, Gorla, Roberto, additional, Lazzaroni, Maria Grazia, additional, Nalli, Cecilia, additional, Taglietti, Marco, additional, Lojacono, Andrea, additional, Zatti, Sonia, additional, Franceschini, Franco, additional, and Tincani, Angela, additional

Published
2020
Full Text
View/download PDF

92. Tapering belimumab in patients with systemic lupus erythematosus: a single-centre experience.

Author

Fredi, Micaela, Vojinovic, Tamara, Regola, Francesca, Babaglioni, Giorgia, Bettoni, Daria, Andreoli, Laura, Tincani, Angela, and Franceschini, Franco

Subjects
*IMMUNOSUPPRESSION, *TREATMENT effectiveness, *MEDICAL protocols, *PATIENTS' attitudes, *DRUG therapy, *SYSTEMIC lupus erythematosus, *PREDNISONE, *BELIMUMAB, *PATIENT safety
Abstract

The article discusses which analyzed the prevalence of tapering belimumab in patients with systemiclupus erythematosu in a single cohort and evaluated disease activity after tapering. Topics covered include the characteristics of patients included in the study, the findings of the analysis of disease activity, and the strengths and limitations of the study.

Published
2023
Full Text
View/download PDF

93. Risk factors of damage in early diagnosed systemic lupus erythematosus: results of the Italian multicentre Early Lupus Project inception cohort

Author

Piga, Matteo, primary, Floris, Alberto, additional, Sebastiani, Gian Domenico, additional, Prevete, Imma, additional, Iannone, Florenzo, additional, Coladonato, Laura, additional, Govoni, Marcello, additional, Bortoluzzi, Alessandra, additional, Mosca, Marta, additional, Tani, Chiara, additional, Doria, Andrea, additional, Iaccarino, Luca, additional, Franceschini, Franco, additional, Fredi, Micaela, additional, Conti, Fabrizio, additional, Spinelli, Francesca Romana, additional, Galeazzi, Mauro, additional, Bellisai, Francesca, additional, Zanetti, Anna, additional, Carrara, Greta, additional, Scirè, Carlo Alberto, additional, and Mathieu, Alessandro, additional

Published
2019
Full Text
View/download PDF

95. Immunosuppressive therapy withdrawal after remission achievement in patients with lupus nephritis.

Author

Zen, Margherita, Fuzzi, Enrico, Martinez, Marta Loredo, Depascale, Roberto, Fredi, Micaela, Gatto, Mariele, Larosa, Maddalena, Saccon, Francesca, Iaccarino, Luca, and Doria, Andrea

Subjects
LUPUS nephritis, BIOPSY, CONFIDENCE intervals, MULTIPLE regression analysis, IMMUNOSUPPRESSION, RISK assessment, PROTEINURIA, DESCRIPTIVE statistics, IMMUNOSUPPRESSIVE agents, PREDNISONE, ODDS ratio, DISEASE remission, DISEASE exacerbation, CREATININE
Abstract

Objectives Whether immunosuppressive therapy may be safely withdrawn in lupus nephritis (LN) is still unclear. We assessed rate and predictors of flare after IS withdrawal in patients with LN in remission. Methods Patients with biopsy-proven LN treated with immunosuppressants (IS) between 1980 and 2020 were considered. Remission was defined as normal serum creatinine, proteinuria <0.5 g/24 h, inactive urine sediment, and no extra-renal SLE activity on stable immunosuppressive and/or antimalarial therapy and/or prednisone ≤5mg/day. IS discontinuation was defined as the complete withdrawal of immunosuppressive therapy, flares according to SLEDAI Flare Index. Predictors of flare were analysed by multivariate logistic regression analysis. Results Among 513 SLE patients included in our database, 270 had LN. Of them, 238 underwent renal biopsy and were treated with IS. Eighty-three patients (34.8%) discontinued IS, 46 (30) months after remission achievement. During a mean (s. d.) follow-up of 116.5 (78) months, 19 patients (22.9%) developed a flare (8/19 renal) and were re-treated; 14/19 (73.7%) re-achieved remission after restarting therapy. Patients treated with IS therapy for at least 3 years after remission achievement had the lowest risk of relapse (OR 0.284, 95% CI: 0.093, 0.867; P = 0.023). At multivariate analysis, antimalarial maintenance therapy (OR 0.194, 95% CI: 0.038, 0.978; P = 0.047), age at IS discontinuation (OR 0.93, 95% CI: 0.868, 0.997; P = 0.040), remission duration >3 years before IS discontinuation (OR 0.231, 95% CI: 0.058, 0.920; P = 0.038) were protective against disease flares. Conclusions Withdrawal of IS is feasible in LN patients in remission for at least 3 years and on antimalarial therapy. Patients who experience flares can re-achieve remission with an appropriate treatment. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

96. Serum IgG2 antibody multi-composition in systemic lupus erythematosus and in lupus nephritis (Part 2): prospective study.

Author

Bruschi, Maurizio, Moroni, Gabriella, Sinico, Renato Alberto, Franceschini, Franco, Fredi, Micaela, Vaglio, Augusto, Cavagna, Lorenzo, Petretto, Andrea, Pratesi, Federico, Migliorini, Paola, Locatelli, Francesco, Pazzola, Giulia, Pesce, Giampaola, Bagnasco, Marcello, Manfredi, Angelo, Ramirez, Giuseppe A, Esposito, Pasquale, Murdaca, Giuseppe, Negrini, Simone, and Cipriani, Leda

Subjects
GLOMERULAR filtration rate, PROTEINS, LUPUS nephritis, IMMUNOGLOBULINS, CONFIDENCE intervals, PROTEINURIA, DESCRIPTIVE statistics, SYSTEMIC lupus erythematosus, ODDS ratio, LONGITUDINAL method
Abstract

Objectives Circulating anti-ENO1 and anti-H2A IgG2 have been identified as specific signatures of LN in a cross-over approach. We sought to show whether the same antibodies identify selected population of patients with LN with potentially different clinical outcomes. Methods Here we report the prospective analysis over 36 months of circulating IgG2 levels in patients with newly diagnosed LN (n =91) and SLE (n =31) and in other patients with SLE recruited within 2 years from diagnosis (n =99). Anti-podocyte (ENO1), anti-nucleosome (DNA, histone 2 A, histone 3) and anti-circulating proteins (C1q, AnnexinA1-ANXA1) IgG2 antibodies were determined by home-made techniques. Results LN patients were the main focus of the study. Anti-ENO1, anti-H2A and anti-ANXA1 IgG2 decreased in parallel to proteinuria and normalized within 12 months in the majority of patients while anti-dsDNA IgG2 remained high over the 36 months. Anti-ENO1 and anti-H2A had the highest association with proteinuria (Heat Map) and identified the highest number of patients with high proteinuria (68% and 71% respectively) and/or with reduced estimated glomerula filtration rate (eGFR) (58% for both antibodies) compared with 23% and 17% of anti-dsDNA (agreement analysis). Anti-ENO1 positive LN patients had higher proteinuria than negative patients at T 0 and presented the maximal decrement within 12 months. Conclusions Anti-ENO1, anti-H2A and anti-ANXA1 antibodies were associated with high proteinuria in LN patients and Anti-ENO1 also presented the maximal reduction within 12 months that paralleled the decrease of proteinuria. Anti-dsDNA were not associated with renal outcome parameters. New IgG2 antibody signatures should be utilized as tracers of personalized therapies in LN. Trial registration The Zeus study was registered at https://clinicaltrials.gov (study number: NCT02403115). [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

97. Serum IgG2 antibody multicomposition in systemic lupus erythematosus and lupus nephritis (Part 1): cross-sectional analysis.

Author

Bruschi, Maurizio, Moroni, Gabriella, Sinico, Renato Alberto, Franceschini, Franco, Fredi, Micaela, Vaglio, Augusto, Cavagna, Lorenzo, Petretto, Andrea, Pratesi, Federico, Migliorini, Paola, Locatelli, Francesco, Pazzola, Giulia, Pesce, Giampaola, Bagnasco, Marcello, Manfredi, Angelo, Ramirez, Giuseppe A, Esposito, Pasquale, Murdaca, Giuseppe, Negrini, Simone, and Cipriani, Leda

Subjects
IMMUNOGLOBULINS, LUPUS nephritis, CROSS-sectional method, DESCRIPTIVE statistics, SYSTEMIC lupus erythematosus, RADIOIMMUNOASSAY
Abstract

Objectives Serum anti-dsDNA and anti-nucleosome IgGs have been proposed as signatures for SLE and LN in limited numbers of patients. We sought to show higher sensitivity and specificity of the same antibodies with the IgG2 isotype and included IgG2 antibodies vs specific intracellular antigens in the analysis. Methods A total of 1052 SLE patients with (n = 479) and without (n = 573) LN, recruited at different times from the beginning of symptoms, were included in the study. Patients with primary APS (PAPS, n = 24), RA (RA, n = 24) and UCTD (UCTD, n = 96) were analysed for comparison. Anti-nucleosome (dsDNA, Histone2A, Histone3), anti-intracellular antigens (ENO1), anti-annexin A1 and anti-C1q IgG2 were determined by non‐commercial techniques. Results The presence in the serum of the IgG2 panel was highly discriminatory for SLE/LN vs healthy subjects. Serum levels of anti-dsDNA and anti-C1q IgG2 were more sensitive than those of IgGs (Farr radioimmunoassay/commercial assays) in identifying SLE patients at low–medium increments. Of more importance, serum positivity for anti-ENO1 and anti-H2A IgG2 discriminated between LN and SLE (ROC T0–12 months), and high levels at T0–1 month were detected in 63% and 67%, respectively, of LN, vs 3% and 3%, respectively, of SLE patients; serum positivity for each of these was correlated with high SLEDAI values. Minor differences existed between LN/SLE and the other rheumatologic conditions. Conclusion Nephritogenic IgG2 antibodies represent a specific signature of SLE/LN, with a few overlaps with other rheumatologic conditions. High levels of anti-ENO1 and anti-H2A IgG2 correlated with SLE activity indexes and were discriminatory between SLE patients limited to the renal complication and other SLE patients. Trial registration The Zeus study was registered at https://clinicaltrials.gov , NCT02403115. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

98. Severe muscle damage with myofiber necrosis and macrophage infiltrates characterize anti-Mi2 positive dermatomyositis.

Author

Fornaro, Marco, Girolamo, Francesco, Cavagna, Lorenzo, Franceschini, Franco, Giannini, Margherita, Amati, Angela, Lia, Anna, Tampoia, Marilina, D'Abbicco, Dario, Maggi, Lorenzo, Fredi, Micaela, Zanframundo, Giovanni, Moschetti, Liala, Coladonato, Laura, and Iannone, Florenzo

Subjects
RESEARCH, MUSCLE diseases, KRUSKAL-Wallis Test, STATISTICS, DERMATOMYOSITIS, SKELETAL muscle, SCIENTIFIC observation, BIOPSY, IMMUNOHISTOCHEMISTRY, MACROPHAGES, RETROSPECTIVE studies, MEDICAL cooperation, CREATINE kinase, HEALTH outcome assessment, FISHER exact test, MANN Whitney U Test, COMPARATIVE studies, T-test (Statistics), DESCRIPTIVE statistics, SURVIVAL analysis (Biometry), HISTOLOGY, ELECTRONIC health records, DATA analysis, DATA analysis software, NECROSIS, LONGITUDINAL method, MIDDLE age
Abstract

Objective The aim of our study was to investigate clinical and histopathological findings in adult DM patients positive for anti-Mi2 (anti-Mi2+) antibodies compared with DM patients negative for anti-Mi2 (anti-Mi2–). Methods Clinical data of adult DM patients, who fulfilled EULAR/ACR 2017 classification criteria, were gathered from electronic medical records of three tertiary Rheumatology Units. Histopathological study was carried out on 12 anti-Mi2+ and 14 anti-Mi2– muscle biopsies performed for diagnostic purpose. Nine biopsies from immune mediated necrotizing myopathy (IMNM) patients were used as control group. Results Twenty-two anti-Mi2+ DM [90.9% female, mean age 56.5 (15.7) years] were compared with 69 anti-Mi2– DM patients [71% female, mean age 52.4 (17) years]. Anti-Mi2+ patients presented higher levels of serum muscle enzymes than anti-Mi2– patients [median (IQR) creatine-kinase fold increment: 16 (7–37) vs 3.5 (1–9.9), P  <0.001] before treatment initiation. Moreover, a trend towards less pulmonary involvement was detected in anti-Mi2+ DM (9.1% vs 30.4%, P  =0.05), without any case of rapidly progressive interstitial lung disease. At muscle histology, anti-Mi2+ patients showed more necrotic/degenerative fibres than anti-Mi2– patients [mean 5.3% (5) vs 0.8% (1), P  <0.01], but similar to IMNM [5.9% (6), P  >0.05]. In addition, the endomysial macrophage score was similar between anti-Mi2+ and IMNM patients [mean 1.2 (0.9) vs 1.3 (0.5), P  >0.05], whereas lower macrophage infiltration was found in anti-Mi2– DM [mean 0.4 (0.5), <0.01]. Conclusions Anti-Mi2+ patients represent a specific DM subset with high muscle damage. Histological hallmarks were a higher prevalence of myofiber necrosis, endomysial involvement and macrophage infiltrates at muscle biopsy. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

99. EEcacy, Safety, and Predictor of Response to Belimumab in a Large Nationwide Cohort Study of Patients with Active Systemic Lupus Erythematosus

Author

Iaccarino, Luca, Saccon, Francesca, Mathieu, Alessandro, Piga, Matteo, Ceribelli, Angela, Selmi, Carlo, Cardinaletti, Paolo, Gabrielli, Armando, Matteo, Andrea Di, Angelis, Rossella De, Faggioli, Paola, Laria, Antonella, Fredi, Micaela, Regola, Francesca, Tincani, Angela, Andreoli, Laura, Pazzola, Giulia, Salvarani, Carlo, Puppo, Francesco, Magnani, Ottavia, Prete, Marcella, Gremese, Elisa, Gerosa, Maria, Ubiali, Tania, Bozzolo, Enrica, Canti, Valentina, Racanelli, Vito, Conti, Fabrizio, Ceccarelli, Fulvia, Bartoloni, Elena, Gerli, Roberto, Lobasso, Antonio, Paulis, Amato De, Marchi, Ginevra De, Vita, Salvatore De, Bortoluzzi, Alessandra, Govoni, Marcello, Benvenuti, Francesco, Zen, Margherita, Mosca, Marta, Tani, Chiara, Rossini, Maurizio, Orsolini, Giovanni, Scarpato, Salvatore, Ernico Brunetta, Zumbo, Aurora, Tanti, Giacomo, Doria, Andrea, Istituto Ortopedico, and Pini, Gaetano

Published
2018
Full Text
View/download PDF

100. Systemic lupus erythematosus: state of the art on clinical practice guidelines

Author

Tamirou, Farah Arnaud, Laurent Talarico, Rosaria Scire, Carlo Alberto Alexander, Tobias Amoura, Zahir Avcin, Tadej and Bortoluzzi, Alessandra Cervera, Ricard Conti, Fabrizio and Cornet, Alain Devilliers, Herve Doria, Andrea Frassi, Micol and Fredi, Micaela Govoni, Marcello Houssiau, Frederic and Llado, Ana Macieira, Carla Martin, Thierry Massaro, Laura and Moraes-Fontes, Maria Francisca Pamfil, Cristina Paolino, Sabrina Tani, Chiara Tas, Sander W. Tektonidou, Maria and Tincani, Angela Van Vollenhoven, Ronald F. Bombardieri, Stefano and Burmester, Gerd Fonseca, Joao Eurico Galetti, Ilaria and Hachulla, Eric Mueller-Ladner, Ulf Schneider, Matthias and Smith, Vanessa Cutolo, Maurizio Mosca, Marta and Costedoat-Chalumeau, Nathalie

Abstract

Systemic lupus erythematosus (SLE) is the paradigm of systemic autoimmune diseases characterised by a wide spectrum of clinical manifestations with an unpredictable relapsing-remitting course. The aim of the present work was to identify current available clinical practice guidelines (CPGs) for SLE, to provide their review and to identify physicians' and patients' unmet needs. Twenty-three original guidelines published between 2004 and 2017 were identified. Many aspects of disease management are covered, including global disease management, lupus nephritis and neuropsychiatric involvement, management of pregnancies, vaccinations and comorbidities monitoring. Unmet needs relate with disease management of some clinical manifestations and adherence to treatment. Many patient's unmet needs have been identified starting with faster diagnosis, need for more therapeutic options, guidelines on lifestyle issues, attention to quality of life and adequate education.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results